The prognostic value can be further increased by combining the data on exosomal Hsp70 with that of other biomarkers in liquid biopsies such as circulating free tumor cell DNA and/or mircoRNA that have been found to be informative for prediction of responses to EFGR inhibitor therapies in NSCLC. This evidence concerns the gene HSPA1A and non-small cell lung carcinoma.